Shows
Pharma Market Access Insights - from Petauri EvidenceTransforming Global Market Access: Smarter Resource Management with Local AffiliatesSend us a textDiscover a smarter way to manage and share market access resources with local affiliatesAre your global market access resources scattered, leading to inconsistencies and confusion among your affiliates? In this webinar we discussed how a centralised platform can streamline resource sharing, ensure access to nationally-relevant evidence, and put the resources your local affiliates need right at their fingertips. The webinar features a conversation with Tim Styche (Market Access & Health Outcomes Director, Smith+Nephew), who shares how his team has solved this challenge with our Global Value Platform.Learn...2025-06-0333 min
Pharma Market Access Insights - from Petauri EvidenceCommunicating value to US Payers: Insights for Pharma and MedtechSend us a textWhat do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging resonates in the US? How do you prepare for launch in a market as diverse as the US?In this Global Whispers episode, Louise Maddison (Senior Consultant – Global Market Access, Petauri Evidence) interviews some of our colleagues from Petauri Advisors who are either former payers, or former industry market access leads in the US. Louise puts your questions to: - 2025-04-2959 min
Pharma Market Access Insights - from Petauri EvidenceNavigating market access: Launch strategies and health economic modelling for medical devicesSend us a textDiscover how health economics can support successful Medical Device launch, proposition development, and market accessThis episode offers an insightful journey into the world of medical device market access. Specialists from our health economics and market access teams explore the hidden challenges faced by medical devices companies when taking new innovations to healthcare leaders, communicating value and demonstrating evidence, and offer tips on leveraging health economics for a successful launch.Juliet Wallace (Senior Partnerships Coordinator) delves deep with our expert panel into the pivotal role of health economic evaluation...2025-04-2444 min
Petauri PACT Executive Briefings - 3-Minute Market InsightsThe Startling Growth of Illegal Online PharmaciesSend us a textThe IQVIA Institute recently reported that there were 15,501 Illegal Online Pharmacies, or I-O-P’s, collectively selling approximately 85 million illegal prescriptions, with an estimated value of $34 billion dollars. At the time of the study, these IOP’s were actively marketing 70% (5,085) of the 7,310 legally prescribed medicines dispensed to patients in the USA.Need more information? Or have suggestions for topics of interest? Please reach out with an email to Insights@ Petauri.comCheck out @Petauri‘s growing library of Executive Briefings where you can listen and download the companion PDF infographics.h...2025-01-1404 minPetauri PACT Executive Briefings - 3-Minute Market InsightsAntimicrobial ResistanceSend us a textAntimicrobial Resistance Could Surpass Cancer as the Leading Cause of Death by 2050. Antimicrobial Resistance is globally recognized as one of the greatest health threats of the 21st century, and yet... we hardly hear anything about it. It’s directly responsible for 1.27 million deaths in 2019 and contributing to 4.95 million deaths overall. Social distancing reduced that number to around 1.14 million in 2021, however by 2050 Antimicrobial Resistance is projected to be associated with over 8 million deaths per year2. According to the World Health Organization (WHO), by 2050 AMR could lead to more deaths tha...2024-12-1003 min
Pharma Market Access Insights - from Petauri EvidenceNavigating US payer evidence needs to optimise market accessSend us a textWhat clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.We explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their ex...2024-11-2757 min
Pharma Market Access Insights - from Petauri EvidenceBest practice RWE approaches to support economic modelling for HTASend us a textHow can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data. Joseph O’Reilly (Principal Medical Statistician, Arcturis) introduces solutions to these challenges using RWD and RWE approaches. Nick Latimer (Analyst, Delta Hat; Prof...2024-11-2059 minPetauri PACT Executive Briefings - 3-Minute Market InsightsBalancing Early Detection and Incidental Findings in Lung Cancer ScreeningSend us a textBalancing Early Detection and Incidental Findings in Lung Cancer Screening Lung cancer is the leading cause of cancer-related deaths globally. While the 5-year survival rate for locally advanced lung cancer is under 5%, early-stage diagnosis can elevate this rate to as high as 60%. Mortality risk factors include age, smoking history, environmental conditions, and social determinants of health. Need more information? Please email us at Insights@Petauri.com.2024-11-2003 minPetauri PACT Executive Briefings - 3-Minute Market InsightsPetauri PACT Executive Briefing - New Branding!Send us a textWelcome to our updated 3-minute Executive Briefing, where we’ve rebranded our program under our new Petauri name. As you are familiar, The Kinetix Group partnered with Petauri Health, a purpose-built pharmaceutical commercialization services platform based in New York City, to expand TKG’s capabilities and enhance the resources and expertise available to our clients. Over the last 18 months, Petauri has expanded rapidly with the addition of multiple best-in-class teams bringing recognized expertise in global market access, medical affairs, patient services, and data analytics. We partner with life sciences companies to effectively engage with...2024-11-1902 min
Pharma Market Access Insights - from Petauri EvidenceNHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to ChristmasSend us a textHow is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months?In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon ICS) to explore these challenges.Jo and Karen discuss:How ICBs and Directors of Commissioning prepare for winter pressuresThe current key areas of focus at Place and ICB levelSpecific challenges and pressures facing the NHS now and in...2024-11-181h 02
Pharma Market Access Insights - from Petauri EvidenceDe-mystifying the NHS – What you need to know about the NHS as a market for your health technologySend us a textAre you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NHS in England? In July 2024, Global Whispers and NHS Whispers came together, to bring you an overarching view of what it takes to access the NHS with a medtech or pharmaceutical innovation.Guest speaker Dr Faris Al-Ramadani who shared his experience of introducing new technologies to the NHS from both sides of the fence: as a...2024-10-1156 min
Pharma Market Access Insights - from Petauri EvidenceNHS primary care panel – the GP Contract and Operational Planning GuidanceSend us a textWhat can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–25?In this webinar, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) spoke to a panel of NHS Associates about the current state and future of primary care and what this means for industry. Our panellists were:- Jack Wagstaff (Place Leader, Surrey Heartlands Health and Care Partnership, Chie...2024-09-101h 02
Pharma Market Access Insights - from Petauri EvidenceEngage NHS healthcare decision-makers with RWDSend us a textDiscover how data visualisation dashboards can aid field teams in market access discussions with customers. Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a well-designed, easy-to-use visualisation can build a case for change, while positioning themselves as a trusted partner. Watch this 20-minute discussion between Iain Shield (Associate Director – Market Access) and Ben Spurr (Head of Partnerships) to discover how Connected Insights data visualisation dashboards can help your teams have strategic conversations with healthcare decision-makers. Iain also explains typical use cases for th...2024-08-1220 min
Pharma Market Access Insights - from Petauri EvidenceMarket access and reimbursement in Canada – changes at CADTHSend us a textWhat do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ottawa).We take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Husereau explore:The market access landscape in CanadaUpcoming changes at CADTHWhat Canadian payers expect from your val...2024-06-2047 min
Pharma Market Access Insights - from Petauri EvidenceRare Disease market access in the MENA and Nordic regionsSend us a textWhere will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?In this webinar, our Global Market Access team compare and contrast access opportunities and challenges for r...2024-05-1059 min
Pharma Market Access Insights - from Petauri EvidenceHow does funding flow in NHSE Regions?Send us a textWhich decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders?We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion that explored finance, funding flows, system priorities, and the decision-making process in NHS Regions.Richard heads up system co-ordination work across the NHS South West Region. The Region has seven Integrated Care Boards (ICBs), 22 Trusts, ni...2024-04-091h 00
Pharma Market Access Insights - from Petauri EvidenceNHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024)Send us a textWhat do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation?Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by guest speakers Debbie Morgan (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Foundation Trust), Ellen Rule (Deputy CEO/Director of Strategy & Transformation, Gloucestershire Integrated Care Board) and Dr Viren Mehta (GP Pa...2024-04-091h 02
Pharma Market Access Insights - from Petauri EvidenceDe-mystifying health economic model classifications and structuresSend us a textWhat is health economic evaluation and which modelling approaches can be used to support market access activities?In this episode, our expert health economists explain the key strengths and limitations of the most common health economic modelling classifications and structures. Here, Hannah Gillies (Consultant – Health Economics) and Daniel MacDonald (Associate Consultant – Health Economics) de-mystify the different approaches to health economic modelling.Our specialists explore six of the most common health economic modelling structures used to support market access activities; - Decision trees - Markov models - Semi-Ma...2024-03-221h 00
Pharma Market Access Insights - from Petauri EvidenceEvidence strategy for Medical Technologies and DiagnosticsSend us a textHere, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies.Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be appropriate for your product? What will payers, HTA agencies, and other key decision makers be looking for? And how should this information be presented?In this episode, our experts in HTA, health economics, and commercialisation explore:- How to...2024-03-1253 min